SRT3 📈 Sartorius Aktiengesellschaft - Overview
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE0007165631
SRT3: Bioreactors, Fermenters, Filtration, Pipettes, Chromatography, Balances, Software
Sartorius Aktiengesellschaft is a leading provider of bioprocess solutions and lab products, catering to a diverse range of industries, including life science research, biopharmaceutical manufacturing, and pharmaceutical quality control. The company's extensive product portfolio encompasses a broad spectrum of equipment and services, including bioreactors, fermenters, cell culture media products, and fluid management systems. These solutions are designed to facilitate the development and production of biopharmaceuticals, vaccines, and other biological products. Additionally, Sartorius offers a range of lab products, such as pipettes, pipette tips, and lab balances, which are essential for various laboratory applications.
The company's product line also includes advanced technologies, such as live-cell analysis systems, reagents, and consumables, which enable researchers to study cellular behavior and interactions. Furthermore, Sartorius provides contract manufacturing and integration services, allowing customers to outsource specific processes and focus on their core activities. The company's process automation platform, software, and data analytics tools help customers optimize their workflows, improve efficiency, and reduce costs. Sartorius also offers a range of chromatography consumables, columns, and systems, which are used in various applications, including biopharmaceutical development and quality control.
Sartorius Aktiengesellschaft has a long history, dating back to 1870, and is headquartered in Göttingen, Germany. The company has established itself as a trusted partner for the life science industry, providing innovative solutions and services that support the development of new therapies and treatments. With a strong focus on research and development, Sartorius continues to expand its product portfolio and services, addressing the evolving needs of its customers. The company's commitment to quality, reliability, and customer satisfaction has earned it a reputation as a leading provider of bioprocess solutions and lab products.
In addition to its product offerings, Sartorius provides a range of services, including bioprocess consulting and engineering, biologics testing, and validation services. These services are designed to support customers in optimizing their bioprocesses, ensuring compliance with regulatory requirements, and improving overall efficiency. The company's expertise in bioprocess development, scale-up, and manufacturing enables it to provide valuable guidance and support to its customers. With its comprehensive portfolio of products and services, Sartorius Aktiengesellschaft is well-positioned to meet the needs of the life science industry, both now and in the future.
The company's customer base is diverse, encompassing pharmaceutical and biotechnology companies, research institutions, and applied industries. Sartorius' solutions are used in various applications, including cell and gene therapy, vaccine development, and biopharmaceutical manufacturing. The company's products and services are designed to support the entire bioprocess workflow, from early-stage research to commercial-scale manufacturing. With its strong industry expertise and commitment to innovation, Sartorius Aktiengesellschaft is a trusted partner for companies and organizations seeking to advance the development of new therapies and treatments.
Additional Sources for SRT3 Stock
SRT3 Stock Overview
Market Cap in USD | 14,873m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception |
SRT3 Stock Ratings
Growth 5y | -15.6% |
Fundamental | 32.2% |
Dividend | 52.8% |
Rel. Strength Industry | -1731 |
Analysts | - |
Fair Price Momentum | 185.92 EUR |
Fair Price DCF | 330.61 EUR |
SRT3 Dividends
Dividend Yield 12m | 0.34% |
Yield on Cost 5y | 0.39% |
Annual Growth 5y | 18.36% |
Payout Consistency | 96.2% |
SRT3 Growth Ratios
Growth Correlation 3m | -73.9% |
Growth Correlation 12m | -80.7% |
Growth Correlation 5y | -25.8% |
CAGR 5y | 2.30% |
CAGR/Mean DD 5y | 0.08 |
Sharpe Ratio 12m | -0.82 |
Alpha | -60.01 |
Beta | 0.84 |
Volatility | 41.14% |
Current Volume | 153k |
Average Volume 20d | 85.8k |
As of December 21, 2024, the stock is trading at EUR 215.60 with a total of 153,007 shares traded.
Over the past week, the price has changed by -6.78%, over one month by +3.35%, over three months by -12.90% and over the past year by -38.03%.
Neither. Based on ValueRay Fundamental Analyses, Sartorius Aktiengesellschaft is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 32.22 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SRT3 as of December 2024 is 185.92. This means that SRT3 is currently overvalued and has a potential downside of -13.77%.
Sartorius Aktiengesellschaft has no consensus analysts rating.
According to ValueRays Forecast Model, SRT3 Sartorius Aktiengesellschaft will be worth about 202.5 in December 2025. The stock is currently trading at 215.60. This means that the stock has a potential downside of -6.1%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 264.4 | 22.6% |
Analysts Target Price | - | - |
ValueRay Target Price | 202.5 | -6.1% |